Med-IQ CME: Is MASH on Your Radar? Screening and Management Strategies
Primary care clinicians and endocrinologists play a critical role in identifying and managing metabolic dysfunction-associated steatohepatitis (MASH) before it progresses. Results from a Med-IQ survey, however, revealed that approximately half of the respondents screen only 50% or fewer of their patients with obesity or type 2 diabetes. Patients with these conditions or other risk factors, such as metabolic syndrome, dyslipidemia, or elevated liver enzymes, should be screened using noninvasive tools like FIB-4, transient elastography (FibroScan), ELF, or VCTE.
Although lifestyle modification remains the cornerstone of treatment, pharmacologic options such as GLP-1 receptor agonists, pioglitazone, and resmetirom may be appropriate based on individual risk profiles. Most patients can be effectively managed in primary care or endocrinology settings, with hepatology referral recommended for patients with a high risk of advanced fibrosis.
Cost: Free
View Offer chevron_rightKey Features
The burden of MASH is growing, but many at-risk patients remain undiagnosed. In this interactive Med-IQ Select activity, discover how you can identify and manage MASH earlier through noninvasive testing and guideline-based treatment strategies.
In this activity, you will:
Get up to speed on the latest AASLD, ADA, AGA, and AACE recommendations
Work through real-world clinical scenarios
Watch video insights from leading experts
Topics Covered
Metabolic dysfunction-associated steatohepatitis (MASH)
Learning Objectives
1. Apply screening pathways for primary and secondary fibrosis risk stratification in patients with risk factors for MASH
2. Select MASH management strategies for patients based on their fibrosis risk stratification and other comorbidities
Target Audience
This activity is intended for family medicine clinicians, primary care physicians, internal medicine clinicians, and endocrinologists
Additional credit info
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.